Skip to content

Insider · CIK 0001779479

Rolph Timothy

officer

Files at AKRO (Akero Therapeutics, Inc.). First filing Dec 12, 2024, latest Dec 18, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $267k sold

Signals

This insider’s open-market buys and sells, scored.

ScoreSideCompanyValueSharesHoldings changePrice contextFiled
5Weaksell 610b5-1AKRO
Akero Therapeutics, Inc.
$118k3,800-2%-
6Weaksell 610b5-1AKRO
Akero Therapeutics, Inc.
$149k4,818-3%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 26, 2024AKRO
Akero Therapeutics, Inc.
GGift
Common Stock
-14,100$0.00$0184,237Dec 30, 2024
Dec 17, 2024AKRO
Akero Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+3,800$19.87$76k182,137Dec 18, 2024
Dec 17, 2024AKRO
Akero Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-3,800$31.10$118k178,337Dec 18, 2024
Dec 16, 2024AKRO
Akero Therapeutics, Inc.
AGrant or award
Common Stock10b5-1
+20,000$0.00$0198,337Dec 18, 2024
Dec 17, 2024AKRO
Akero Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-3,800$0.00$0134,955Dec 18, 2024
Dec 16, 2024AKRO
Akero Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative10b5-1
+60,000$0.00$060,000Dec 18, 2024
Dec 10, 2024AKRO
Akero Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-2,368$30.79$73k178,337Dec 12, 2024
Dec 10, 2024AKRO
Akero Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+2,450$19.87$49k180,787Dec 12, 2024
Dec 10, 2024AKRO
Akero Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-2,450$31.03$76k178,337Dec 12, 2024
Dec 10, 2024AKRO
Akero Therapeutics, Inc.
MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,450$0.00$0138,755Dec 12, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.